Ribon Therapeutics

Biotechnology ResearchMassachusetts, United States2-10 Employees

Ribon Therapeutics is a clinical-stage biotechnology company based in Cambridge, Massachusetts. It focuses on discovering and developing small-molecule inhibitors that block the fundamental ability of cancer cells to survive under stress, addressing a key survival mechanism in tumors. The company operates within the biotechnology research industry, emphasizing stress-support pathways as the core area of its research. With a small team, Ribon concentrates its efforts on translating cellular-stress biology into potential cancer therapies.

In late 2022, Ribon announced an agreement with Boehringer Ingelheim related to its CD38 program, illustrating its use of external collaborations to advance its portfolio. The organization pursues oncology applications and seeks partnerships to move its science toward clinical development.

Sign up for free to view info

Email Format Employee directory